Herrick, A. L., Assassi, S. & Denton, C. P. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nat. Rev. Rheumatol. 18, 276–285 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Jiang, Y., Turk, M. A. & Pope, J. E. Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). Autoimmun. Rev. 19, 102602 (2020).

Article  CAS  PubMed  Google Scholar 

Attanasio, U. et al. Pulmonary hypertension phenotypes in systemic sclerosis: the right diagnosis for the right treatment. Int. J. Mol. Sci. 21, 4430 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siqueira, V. S. et al. Predictors of progression to systemic sclerosis: analysis of very early diagnosis of systemic sclerosis in a large single-centre cohort. Rheumatology 61, 3686–3692 (2022).

Article  CAS  PubMed  Google Scholar 

Domsic, R. T. et al. Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology 60, 4662–4670 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Higley, H. et al. Immunocytochemical localization and serologic detection of transforming growth factor β1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud’s phenomenon. Arthritis Rheum. 37, 278–288 (1994).

Article  CAS  PubMed  Google Scholar 

Tsou, P. S., Shi, B. & Varga, J. Role of cellular senescence in the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. 34, 343–350 (2022).

Article  CAS  PubMed  Google Scholar 

Lescoat, A., Lecureur, V. & Varga, J. Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications. Curr. Opin. Rheumatol. 33, 463–470 (2021).

Article  CAS  PubMed  Google Scholar 

Tsou, P. S., Varga, J. & O’Reilly, S. Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential. Nat. Rev. Rheumatol. 17, 596–607 (2021).

Article  PubMed  Google Scholar 

Shah, S. & Denton, C. P. Scleroderma autoantibodies in guiding monitoring and treatment decisions. Curr. Opin. Rheumatol. 34, 302–310 (2022).

Article  CAS  PubMed  Google Scholar 

Lescoat, A., Varga, J., Matucci-Cerinic, M. & Khanna, D. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert. Opin. Investig. Drugs 30, 635–652 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518–2528 (2019).

Article  CAS  PubMed  Google Scholar 

Haynes, D. C. & Gershwin, M. E. The immunopathology of progressive systemic sclerosis (PSS). Semin. Arthritis Rheum. 11, 331–351 (1982).

Article  CAS  PubMed  Google Scholar 

Sappino, A. P., Masouyé, I., Saurat, J. H. & Gabbiani, G. Smooth muscle differentiation in scleroderma fibroblastic cells. Am. J. Pathol. 137, 585–591 (1990).

CAS  PubMed  PubMed Central  Google Scholar 

Kirk, T. Z., Mark, M. E., Chua, C. C., Chua, B. H. & Mayes, M. D. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J. Biol. Chem. 270, 3423–3428 (1995).

Article  CAS  PubMed  Google Scholar 

Krieg, T., Perlish, J. S., Mauch, C. & Fleischmajer, R. Collagen synthesis by scleroderma fibroblasts. Ann. N. Y. Acad. Sci. 460, 375–386 (1985).

Article  CAS  PubMed  Google Scholar 

LeRoy, E. C. The pathogenesis of systemic sclerosis. Clin. Exp. Rheumatol. 7, S135–S137 (1989).

PubMed  Google Scholar 

Mauch, C. & Kreig, T. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum. Dis. Clin. North. Am. 16, 93–107 (1990).

Article  CAS  PubMed  Google Scholar 

van der Slot, A. J. et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J. Biol. Chem. 278, 40967–40972 (2003).

Article  PubMed  Google Scholar 

Ivarsson, M., McWhirter, A., Black, C. M. & Rubin, K. Impaired regulation of collagen pro-α1(I) mRNA and change in pattern of collagen-binding integrins on scleroderma fibroblasts. J. Invest. Dermatol. 101, 216–221 (1993).

Article  CAS  PubMed  Google Scholar 

Bou-Gharios, G., Osman, J., Black, C. & Olsen, I. Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis. Clin. Chim. Acta 231, 69–78 (1994).

Article  CAS  PubMed  Google Scholar 

Wakhlu, A. et al. Assessment of extent of skin involvement in scleroderma using shear wave elastography. Indian. J. Rheumatol. 12, 194–198 (2017).

Article  Google Scholar 

Aden, N. et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology 47, 1754–1760 (2008).

Article  CAS  PubMed  Google Scholar 

Allanore, Y. et al. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J. Rheumatol. 30, 68–73 (2003).

CAS  PubMed  Google Scholar 

Lurje, I., Gaisa, N. T., Weiskirchen, R. & Tacke, F. Mechanisms of organ fibrosis: emerging concepts and implications for novel treatment strategies. Mol. Asp. Med. 92, 101191 (2023).

Article  CAS  Google Scholar 

Brown, M. & O’Reilly, S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin. Exp. Immunol. 195, 310–321 (2019).

Article  CAS  PubMed  Google Scholar 

van Bon, L., Cossu, M. & Radstake, T. R. An update on an immune system that goes awry in systemic sclerosis. Curr. Opin. Rheumatol. 23, 505–510 (2011).

Article  PubMed  Google Scholar 

Wei, L., Abraham, D. & Ong, V. The Yin and Yang of IL-17 in systemic sclerosis. Front. Immunol. 13, 885609 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Worrell, J. C. & O’Reilly, S. Bi-directional communication: conversations between fibroblasts and immune cells in systemic sclerosis. J. Autoimmun. 113, 102526 (2020).

Article  CAS  PubMed  Google Scholar 

Li, G. et al. Skin-resident effector memory CD8+CD28− T cells exhibit a profibrotic phenotype in patients with systemic sclerosis. J. Invest. Dermatol. 137, 1042–1050 (2017).

Article  CAS  PubMed  Google Scholar 

Yaseen, B. et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology 59, 2625–2636 (2020).

Article  CAS  PubMed  Google Scholar 

Makhluf, H. A. et al. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J. Invest. Dermatol. 107, 856–859 (1996).

Article  CAS  PubMed  Google Scholar 

Matsushita, T. et al. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci. Adv. 4, eaas9944 (2018).

Article  PubMed  PubMed Central  Google Scholar 

François, A. et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res. Ther. 15, R168 (2013).

Article  PubMed  PubMed Central  Google Scholar 

Matsushita, T. et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54, 192–201 (2006).

Article  CAS  PubMed  Google Scholar 

van der Kroef, M. et al. CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: implications for systemic sclerosis. J. Autoimmun. 111, 102444 (2020).

Article  PubMed  Google Scholar 

Binai, N., O’Reilly, S., Griffiths, B., van Laar, J. M. & Hügle, T. Differentiation potential of CD14+ monocytes into myofibroblasts in patients with systemic sclerosis. PLoS ONE 7, e33508 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Herrick, A. L. et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann. Rheum. Dis. 76, 1207–1218 (2017).

Article